USFDA issues final approval to Alembic for Pirfenidone tablets

It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses, the statement said.

301
USFDA Drug product Approval
USFDA Approval

Last Updated on December 24, 2023 by The Health Master

Alembic Pharma received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Pirfenidone tablets, 267 mg and 801 mg.

The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Esbriet tablets, 267 mg and 801 mg, of Genentech, according to a statement from Alembic Pharma.

Pirfenidone Tablets are indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Alembic had previously received tentative approval for this ANDA.

The company was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification.

It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses, the statement said.

Pirfenidone Tablets, 267 mg and 801 mg have an estimated market size of $548 million for 12 months ending December 2021, according to IQVIA. Alembic has settled the case with Genetech, and will launch its generic as per the terms of settlement, the statement concluded.

USFDA gives nod to Glenmark for Abiraterone Acetate tablets USP 500 mg

USFDA approves Oral Form for the treatment of Amyotrophic lateral sclerosis (ALS)

USFDA gives nod to Sun Pharma Mesalamine extended release capsules

USFDA gives approval to Alembic Pharma for Arformoterol Tartrate Inhalation Solution

USFDA gives tentative nod to Glenmark for Calcipotriene and Betamethasone Dipropionate foam

USFDA gives tentative approval for this Hypertension drug

These important medical drugs are found in plants

De-addiction center raided by joint team of FDA Haryana & Police: HM

Drug recall: Over 10,000 bottles of generic Anti-depression Drug recalled

Financial aid to the family of late Sh. Sudip Ganguly, Drug Inspector West Bengal

Govt adds psoriasis drug Acitretin under Schedule H of Drugs Rules

NPPA has launched an exercise to cap the huge margins of medicines

FDA lodged FIR for manufacturing BP monitoring machines without license

USFDA gives nod to Glenmark for Abiraterone Acetate tablets USP 500 mg

FAQs – on Schedule-P (Expiry Date of drugs)

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news